Mesothelioma

Mesothelioma Trials News

Eli Lilly to buy ImClone for more than $6 billionMonday, October 6, 2008 @ 1:32PMEli Lilly & Co. has agreed to spend more than $6 billion to fortify its cancer treatment portfolio by acquiring the biotechnology firm ImClone Systems Inc. in a deal that tops earlier offers from competitor Bristol-Myers Squibb Co.

CytRx Corporation Completes Acquisition of Innovive Pharmaceuticals, Inc.Monday, September 22, 2008 @ 8:30AM LOS ANGELES----CytRx Corporation , a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced the completion of its acquisition of Innovive Pharmaceuticals, Inc.

LegalView Informs Mesothelioma Blog Readers of a Predicted Increase in Female Mesothelioma VictimsMonday, July 21, 2008 @ 6:13AM LegalView updated readers to an alarming prediction by researchers who said the number of female mesothelioma victims may increase within the next few years. Researchers said that asbestos in hair dryers that were previously unregulated may be the cause. (PRWeb Jul 21, 2008) Read the full story at http://www.prweb.com/releases/2008/07/prweb1127814.htm

LegalView Informs Mesothelioma Blog Readers of a Predicted Increase in Female Mesothelioma VictimsMonday, July 21, 2008 @ 3:01AM LegalView updated readers to an alarming prediction by researchers who said the number of female mesothelioma victims may increase within the next few years. Researchers said that asbestos in hair dryers that were previously unregulated may be the cause.

Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory ...Tuesday, June 3, 2008 @ 9:15AM Keryx Biopharmaceuticals, Inc. today announced that phase 2 results of perifosine in patients with relapsed/refractory Waldenstroms macroglobulinemia was presented at the 44th Annual Meeting of the American Society of Clinical Oncology.

Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT MeetingFriday, May 30, 2008 @ 7:30AM Oncolytics Biotech Inc. announced today that two presentations covering preclinical work using the reovirus are scheduled to be delivered by Dr. Richard Vile of the Mayo College of Medicine, Rochester, Minnesota, at the American Society of Gene Therapy annual meeting in Boston, MA.

Strativa Pharmaceuticals Announces Preliminary Results From ONCONASE Phase IIIb Clinical TrialFriday, May 30, 2008 @ 2:16AMStrativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. recently announced that its development partner, Alfacell Corporation reported that the preliminary statistical analysis of data from its confirmatory Phase IIIb clinical trial of its lead compound, ONCONASE (ranpirnase), did not meet statistical significance for the primary endpoint of survival in ...

Clear Channel, Parmalat, Wyeth, UBS in Court News (Update1)Wednesday, April 30, 2008 @ 1:06AMApril 30 (Bloomberg) -- Citigroup Inc. and five other banks lost a bid to delay until next year a Texas trial over a Clear Channel Communications Inc.